文献速递甲状腺核医学肿瘤 PET/CT放射性药物与辐射防护

18F-四氟硼酸盐(18F-TFB)在健康人体中的安全性、药代动力学、代谢与辐射剂量学研究

Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects.
PubMed 文献 · EJNMMI Res · 2017-10-27

本研究在8名健康志愿者中评估了高比活度18F-TFB的安全性、药代动力学、生物分布与辐射剂量学,受试者耐受良好,血液和尿液中未见明显18F标记代谢物,甲状腺、胃、唾液腺和膀胱摄取高,男性有效剂量为0.036 mSv/MBq,女性为0.064 mSv/MBq(p=0.08,无显著差异)。

要点

  • 18F-TFB在健康受试者中耐受良好,生命体征和临床实验室检查无临床意义的变化。
  • 血液和尿液中18F标记代谢物在整个4小时研究期间不显著,骨摄取低提示代谢稳定。
  • 甲状腺、胃、唾液腺和膀胱摄取高,泌尿清除显著,男性有效剂量0.036 mSv/MBq,女性0.064 mSv/MBq。

核心结论

  • 这项在健康人体中进行的初步研究显示18F-TFB是安全的,其在人体内的分布与其他碘类似物相似。
  • 这些数据支持进一步开展18F-TFB作为NIS基因报告基因以及甲状腺癌和其他碘转运疾病影像生物标志物的转化研究。

研究设计与样本

  • 研究纳入4名女性和4名男性健康志愿者,年龄35±11岁,静脉注射18F-TFB(333-407 MBq)后进行4小时内的动态和全身静态PET/CT扫描。
  • 18F-TFB合成时比活度为3.2±1.3 GBq/μmol(合成结束时)。
  • 在成像期间采集静脉血和尿液样本,用离子色谱HPLC分析示踪剂稳定性。
  • 测量生命体征和临床实验室安全指标以评估安全性。

主要发现

  • 18F-TFB给药耐受良好,生命体征无显著异常发现,临床实验室检查无临床意义的变化。
  • 左心室血池时间-放射性曲线显示18F放射性多相血液清除,前20分钟内有两个快速清除相,随后为较慢的清除相。
  • HPLC分析显示在整个研究期间(4小时)血液和尿液中18F标记代谢物不显著。
  • 甲状腺、胃、唾液腺和膀胱可见高摄取,18F-TFB的泌尿清除显著。
  • 骨中18F放射性蓄积低,提示代谢稳定性。

关键数值与推荐

  • 男性有效剂量为0.036 mSv/MBq,女性为0.064 mSv/MBq(p=0.08,无显著差异)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 18F-Tetrafluoroborate (18F-TFB) is a promising iodide analog for PET imaging of thyroid cancer and sodium/iodide symporter (NIS) reporter activity in viral therapy applications. The aim of this study was to evaluate the safety, pharmacokinetics, biodistribution, and radiation dosimetry of high-specific activity 18F-TFB in healthy human subjects. METHODS: 18F-TFB was synthesized with specific activity of 3.2 ± 1.3 GBq/μmol (at the end of synthesis). Dynamic and whole-body static PET/CT scans over 4 h were performed after intravenous administration of 18F-TFB (333-407 MBq) in four female and four male healthy volunteers (35 ± 11 years old). Samples of venous blood and urine were collected over the imaging period and analyzed by ion-chromatography HPLC to determine tracer stability. Vital signs and clinical laboratory safety assays were measured to evaluate safety. RESULTS: 18F-TFB administration was well tolerated with no significant findings on vital signs and no clinically meaningful changes in clinical laboratory assays. Left-ventricular blood pool time-activity curves showed a multi-phasic blood clearance of 18F-radioactivity with the two rapid clearance phases over the first 20 min, followed by a slower clearance phase. HPLC analysis showed insignificant 18F-labeled metabolites in the blood and urine over the length of the study (4 h). High uptakes were seen in the thyroid, stomach, salivary glands, and bladder. Urinary clearance of 18F-TFB was prominent. Metabolic stability was evidenced by low accumulation of 18F-radioactivity in the bone. Effective doses were 0.036 mSv/MBq in males and 0.064 mSv/MBq in females (p = 0.08, not significant). CONCLUSIONS: This initial study in healthy human subjects showed 18F-TFB was safe and distributed in the human body similar to other iodide analogs. These data support further translational studies with 18F-TFB as NIS gene reporter and imaging biomarker for thyroid cancer and other disease processes that import iodide.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Jiang H, Schmit NR, Koenen AR, et al. Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects. EJNMMI Res. 2017. PMID: 29080017. doi:10.1186/s13550-017-0337-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。